"Every company I know of is interested in this, " says Plexxikon Chief Executive Peter Hirth.

FORBES: Magazine Article

Dr. Hirth's team focused on finding drugs to silence growth receptors on the tumors themselves.

FORBES: Targeting Tumors

Dr. Hirth had owned about 1% of the outfit and received Pharmacia stock in the deal.

FORBES: Targeting Tumors

Dr. Hirth, at the time a 40-year-old research manager at Boehringer Mannheim, was intrigued by this concept, but his employer had little interest.

FORBES: Targeting Tumors

Today Dr. Hirth's bold move is close to paying off.

FORBES: Targeting Tumors